CONCIZUMAB

UNII:	68603V9EAF
Formula:
Preferred Substance Name:	CONCIZUMAB

1312299-39-0
ALHEMO
CONCIZUMAB [INN]
CONCIZUMAB [JAN]
CONCIZUMAB [USAN]
CONCIZUMAB [WHO-DD]
CONCIZUMAB-MTCI
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS TFPI (TISSUE FACTOR PATHWAY INHIBITOR, LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR)), HUMANIZED MONOCLONAL ANTIBODY
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS TISSUE FACTOR PATHWAY INHIBITOR (LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR, TFPI))HUMANIZED MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-448) (HUMANIZED VH (HOMO SAPIENS IGHV3-21*01 (86%) (IGHD)-IGHJ6*01 (93%)) (8.8.14) (1-121)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(229))) (122-448)) (135-219')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-219') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV2-29*02 (90%) IGKJ4*01)(11.3.9) (1'-112')-HOMO SAPIENS IGKC*01 (113'-219')), DIMER (227-227'':230-230'')-BISDISULFIDE
MAB2021
MAB-2021
NN7415
NN-7415
NNC-0172-0000-2021
NNC01722021
NNC0172-2021
NNC172-2021

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CONCIZUMAB

Synonyms and Mappings

Resources